Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELVN-002 + trastuzumab + eribulin (Enliven Therapeutics)
- Development stage
- Unknown
- Lead developer
- Enliven Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ELVN-002 + trastuzumab + eribulin is a combination therapy regimen being evaluated by Enliven Therapeutics for the treatment of HER2-positive solid tumors, including breast, colorectal, and gastric cancers. The regimen consists of three components: ELVN-002, a potent, highly selective, and irreversible small molecule tyrosine kinase inhibitor (TKI) designed to target both wild-type HER2 and various HER2 mutations while sparing EGFR; trastuzumab, a HER2-targeted monoclonal antibody; and eribulin, a microtubule inhibitor chemotherapy. This triplet combination aims to provide comprehensive HER2 blockade through dual targeting (extracellular and intracellular) alongside the cytotoxic effects of eribulin. ELVN-002 is specifically engineered to be CNS-penetrant, addressing a significant need in patients with brain metastases. As of 2024, the combination is in Phase 1 development (NCT05650879). However, Enliven Therapeutics has announced plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025 in order to focus on its leukemia candidates.
- Brand names
- HalavenHerceptin
- Other names
- eribulintrastuzumaberibulin mesylateELVN002ELVN-002ELVN 002
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ELVN-002 + trastuzumab + eribulin (Enliven Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELVN-002 + trastuzumab + eribulin (Enliven Therapeutics).